Nature Communications (Apr 2021)
PAX8 and MECOM are interaction partners driving ovarian cancer
- Melusine Bleu,
- Fanny Mermet-Meillon,
- Verena Apfel,
- Louise Barys,
- Laura Holzer,
- Marianne Bachmann Salvy,
- Rui Lopes,
- Inês Amorim Monteiro Barbosa,
- Cecile Delmas,
- Alexandra Hinniger,
- Suzanne Chau,
- Markus Kaufmann,
- Simon Haenni,
- Karolin Berneiser,
- Maria Wahle,
- Ivana Moravec,
- Alexandra Vissières,
- Tania Poetsch,
- Erik Ahrné,
- Nathalie Carte,
- Johannes Voshol,
- Elisabeth Bechter,
- Jacques Hamon,
- Marco Meyerhofer,
- Dirk Erdmann,
- Matteo Fischer,
- Therese Stachyra,
- Felix Freuler,
- Sascha Gutmann,
- César Fernández,
- Tobias Schmelzle,
- Ulrike Naumann,
- Guglielmo Roma,
- Kate Lawrenson,
- Cristina Nieto-Oberhuber,
- Amanda Cobos-Correa,
- Stephane Ferretti,
- Dirk Schübeler,
- Giorgio Giacomo Galli
Affiliations
- Melusine Bleu
- Disease area Oncology, Novartis Institutes for Biomedical Research
- Fanny Mermet-Meillon
- Disease area Oncology, Novartis Institutes for Biomedical Research
- Verena Apfel
- Disease area Oncology, Novartis Institutes for Biomedical Research
- Louise Barys
- Disease area Oncology, Novartis Institutes for Biomedical Research
- Laura Holzer
- Disease area Oncology, Novartis Institutes for Biomedical Research
- Marianne Bachmann Salvy
- Disease area Oncology, Novartis Institutes for Biomedical Research
- Rui Lopes
- Disease area Oncology, Novartis Institutes for Biomedical Research
- Inês Amorim Monteiro Barbosa
- Disease area Oncology, Novartis Institutes for Biomedical Research
- Cecile Delmas
- Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research
- Alexandra Hinniger
- Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research
- Suzanne Chau
- Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research
- Markus Kaufmann
- Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research
- Simon Haenni
- Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research
- Karolin Berneiser
- Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research
- Maria Wahle
- Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research
- Ivana Moravec
- Analytical Sciences and Imaging, Novartis Institutes for Biomedical Research
- Alexandra Vissières
- Analytical Sciences and Imaging, Novartis Institutes for Biomedical Research
- Tania Poetsch
- Analytical Sciences and Imaging, Novartis Institutes for Biomedical Research
- Erik Ahrné
- Analytical Sciences and Imaging, Novartis Institutes for Biomedical Research
- Nathalie Carte
- Analytical Sciences and Imaging, Novartis Institutes for Biomedical Research
- Johannes Voshol
- Analytical Sciences and Imaging, Novartis Institutes for Biomedical Research
- Elisabeth Bechter
- Disease area Oncology, Novartis Institutes for Biomedical Research
- Jacques Hamon
- Disease area Oncology, Novartis Institutes for Biomedical Research
- Marco Meyerhofer
- Disease area Oncology, Novartis Institutes for Biomedical Research
- Dirk Erdmann
- Disease area Oncology, Novartis Institutes for Biomedical Research
- Matteo Fischer
- Disease area Oncology, Novartis Institutes for Biomedical Research
- Therese Stachyra
- Disease area Oncology, Novartis Institutes for Biomedical Research
- Felix Freuler
- Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research
- Sascha Gutmann
- Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research
- César Fernández
- Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research
- Tobias Schmelzle
- Disease area Oncology, Novartis Institutes for Biomedical Research
- Ulrike Naumann
- Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research
- Guglielmo Roma
- Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research
- Kate Lawrenson
- Cedars-Sinai Women’s Cancer Program at the Samuel Oschin Cancer Center
- Cristina Nieto-Oberhuber
- Global Discovery Chemistry, Novartis Institutes for Biomedical Research
- Amanda Cobos-Correa
- Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research
- Stephane Ferretti
- Disease area Oncology, Novartis Institutes for Biomedical Research
- Dirk Schübeler
- Friedrich Miescher Institute for Biomedical Research, University of Basel
- Giorgio Giacomo Galli
- Disease area Oncology, Novartis Institutes for Biomedical Research
- DOI
- https://doi.org/10.1038/s41467-021-22708-w
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 12
Abstract
Lineage-restricted transcription factor PAX8 is oncogenic in ovarian cancer cells. Here the authors show that PAX8 interacts and recruits a splice variant of the MECOM locus PRDM3 to control the gene expression module involved in adhesion and extracellular matrix, and consequently promotes ovarian tumorigenesis.
